Cargando…
In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry
INTRODUCTION: (177)Lu-OPS201 is a high-affinity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroendocrine tumors. The aim is to find the optimal scaling for dosimetry and to compare the biokinetics of (177)Lu-OPS201 in animals and humans. METHODS: Data on biokinetics of (17...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348830/ https://www.ncbi.nlm.nih.gov/pubmed/30733648 http://dx.doi.org/10.1155/2019/6438196 |
_version_ | 1783390176213467136 |
---|---|
author | Beykan, Seval Fani, Melpomeni Jensen, Svend Borup Nicolas, Guillaume Wild, Damian Kaufmann, Jens Lassmann, Michael |
author_facet | Beykan, Seval Fani, Melpomeni Jensen, Svend Borup Nicolas, Guillaume Wild, Damian Kaufmann, Jens Lassmann, Michael |
author_sort | Beykan, Seval |
collection | PubMed |
description | INTRODUCTION: (177)Lu-OPS201 is a high-affinity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroendocrine tumors. The aim is to find the optimal scaling for dosimetry and to compare the biokinetics of (177)Lu-OPS201 in animals and humans. METHODS: Data on biokinetics of (177)Lu-OPS201 were analyzed in athymic nude Foxn1 (nu) mice (28 F, weight: 26 ± 1 g), Danish Landrace pigs (3 F-1 M, weight: 28 ± 2 kg), and patients (3 F-1 M, weight: 61 ± 17 kg) with administered activities of 0.19–0.27 MBq (mice), 97–113 MBq (pigs), and 850–1086 MBq (patients). After euthanizing mice (up to 168 h), the organ-specific activity contents (including blood) were measured. Multiple planar and SPECT/CT scans were performed until 250 h (pigs) and 72 h (patients) to quantify the uptake in the kidneys and liver. Blood samples were taken up to 23 h (patients) and 300 h (pigs). In pigs and patients, kidney protection was applied. Time-dependent uptake data sets were created for each species and organ/tissue. Biexponential fits were applied to compare the biokinetics in the kidneys, liver, and blood of each species. The time-integrated activity coefficients (TIACs) were calculated by using NUKFIT. To determine the optimal scaling, several methods (relative mass scaling, time scaling, combined mass and time scaling, and allometric scaling) were compared. RESULTS: A fast blood clearance of the compound was observed in the first phase (<56 h) for all species. In comparison with patients, pigs showed higher liver retention. Based on the direct comparison of the TIACs, an underestimation in mice (liver and kidneys) and an overestimation in pigs' kidneys compared to the patient data (kidney TIAC: mice = 1.4 h, pigs = 7.7 h, and patients = 5.8 h; liver TIAC: mice = 0.7 h, pigs = 4.1 h, and patients = 5.3 h) were observed. Most similar TIACs were obtained by applying time scaling (mice) and combined scaling (pigs) (kidney TIAC: mice = 3.9 h, pigs = 4.8 h, and patients = 5.8 h; liver TIAC: mice = 0.9 h, pigs = 4.7 h, and patients = 5.3 h). CONCLUSION: If the organ mass ratios between the species are high, the combined mass and time scaling method is optimal to minimize the interspecies differences. The analysis of the fit functions and the TIACs shows that pigs are better mimicking human biokinetics. |
format | Online Article Text |
id | pubmed-6348830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-63488302019-02-07 In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry Beykan, Seval Fani, Melpomeni Jensen, Svend Borup Nicolas, Guillaume Wild, Damian Kaufmann, Jens Lassmann, Michael Contrast Media Mol Imaging Research Article INTRODUCTION: (177)Lu-OPS201 is a high-affinity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroendocrine tumors. The aim is to find the optimal scaling for dosimetry and to compare the biokinetics of (177)Lu-OPS201 in animals and humans. METHODS: Data on biokinetics of (177)Lu-OPS201 were analyzed in athymic nude Foxn1 (nu) mice (28 F, weight: 26 ± 1 g), Danish Landrace pigs (3 F-1 M, weight: 28 ± 2 kg), and patients (3 F-1 M, weight: 61 ± 17 kg) with administered activities of 0.19–0.27 MBq (mice), 97–113 MBq (pigs), and 850–1086 MBq (patients). After euthanizing mice (up to 168 h), the organ-specific activity contents (including blood) were measured. Multiple planar and SPECT/CT scans were performed until 250 h (pigs) and 72 h (patients) to quantify the uptake in the kidneys and liver. Blood samples were taken up to 23 h (patients) and 300 h (pigs). In pigs and patients, kidney protection was applied. Time-dependent uptake data sets were created for each species and organ/tissue. Biexponential fits were applied to compare the biokinetics in the kidneys, liver, and blood of each species. The time-integrated activity coefficients (TIACs) were calculated by using NUKFIT. To determine the optimal scaling, several methods (relative mass scaling, time scaling, combined mass and time scaling, and allometric scaling) were compared. RESULTS: A fast blood clearance of the compound was observed in the first phase (<56 h) for all species. In comparison with patients, pigs showed higher liver retention. Based on the direct comparison of the TIACs, an underestimation in mice (liver and kidneys) and an overestimation in pigs' kidneys compared to the patient data (kidney TIAC: mice = 1.4 h, pigs = 7.7 h, and patients = 5.8 h; liver TIAC: mice = 0.7 h, pigs = 4.1 h, and patients = 5.3 h) were observed. Most similar TIACs were obtained by applying time scaling (mice) and combined scaling (pigs) (kidney TIAC: mice = 3.9 h, pigs = 4.8 h, and patients = 5.8 h; liver TIAC: mice = 0.9 h, pigs = 4.7 h, and patients = 5.3 h). CONCLUSION: If the organ mass ratios between the species are high, the combined mass and time scaling method is optimal to minimize the interspecies differences. The analysis of the fit functions and the TIACs shows that pigs are better mimicking human biokinetics. Hindawi 2019-01-03 /pmc/articles/PMC6348830/ /pubmed/30733648 http://dx.doi.org/10.1155/2019/6438196 Text en Copyright © 2019 Seval Beykan et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Beykan, Seval Fani, Melpomeni Jensen, Svend Borup Nicolas, Guillaume Wild, Damian Kaufmann, Jens Lassmann, Michael In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry |
title | In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry |
title_full | In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry |
title_fullStr | In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry |
title_full_unstemmed | In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry |
title_short | In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry |
title_sort | in vivo biokinetics of (177)lu-ops201 in mice and pigs as a model for predicting human dosimetry |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348830/ https://www.ncbi.nlm.nih.gov/pubmed/30733648 http://dx.doi.org/10.1155/2019/6438196 |
work_keys_str_mv | AT beykanseval invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry AT fanimelpomeni invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry AT jensensvendborup invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry AT nicolasguillaume invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry AT wilddamian invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry AT kaufmannjens invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry AT lassmannmichael invivobiokineticsof177luops201inmiceandpigsasamodelforpredictinghumandosimetry |